The oncogenic effects of ROS1 are based on the constitutively phosphorylated and activated by the fusions with partner genes, such as CD74 (most common),166FIG (fused in glioblastoma, the oncogenic effect of ROS1 rearrangements first identified),167SLC34A2 (so lute carrier family 34 member 2),168 and so on. The gene discussed is ROS1; the disease is glioblastoma.